Noticias y Actividades de HotSpot Therapeutics
Ejecutivos
Ver el organigrama con sus 17 ejecutivos principales
Biografías más buscadas en HotSpot Therapeutics
- Jonathan Montagu, Chief Executive Officer and Director
- Graziano Seghezzi, Director
- Jill Carroll, Director
Recientes movimientos de ejecutivos en HotSpot Therapeutics
- Timothy Reilly, Chief Development Officer, ha dejado la empresa (noticia publicada el 3 de febrero de 2025).
- Alison O'Neill, se ha incorporado a la empresa como Chief Medical Officer (noticia publicada el 20 de septiembre de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en HotSpot Therapeutics.
Biotecnología
HotSpot Therapeutics tiene 2.340 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Biogen (Estados Unidos).
Popular M&A news in Biotecnología
- Biolinq acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 23 de abril de 2025).
- Glycomine acaba de anunciar una recaudación de fondos de 115 millones de dólares. (publicado el 22 de abril de 2025).
- Attovia Therapeutics acaba de anunciar una recaudación de fondos de 90 millones de dólares. (publicado el 21 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de HotSpot Therapeutics
- HotSpot Therapeutics Presents Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium - HotSpot Therapeutics
- HotSpot Therapeutics to Present Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium - HotSpot Therapeutics
- HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics Appoints Alison O’Neill, M.D., as Chief Medical Officer - HotSpot Therapeutics
- HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024 - HotSpot Therapeutics
- HotSpot Therapeutics to Present Initial First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024 - HotSpot Therapeutics
- HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma - HotSpot Therapeutics
- HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting - HotSpot Therapeutics
- HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting - HotSpot Therapeutics
- View more press releases Close
Redes sociales sobre HotSpot Therapeutics
- HotSpot Therapeutics en Wikipedia, Google News y Yahoo Finance
- HotSpot Therapeutics en LinkedIn, Twitter y YouTube
